Published 4 days ago • loading... • Updated 4 days ago

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 ...

Summary by Hastings Tribune

Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling

1 Articles

All

Left

Center

Right

Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling

4 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated4 days agoBias Distribution

100% Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in 4 days ago on Monday, May 12, 2025.

Sources are mostly out of (0)